Контроль над бронхиальной астмой и малые дыхательные пути: существует ли взаимосвязь?
https://doi.org/10.18093/0869-0189-2012-0-6-127-134
Аннотация
Контроль над бронхиальной астмой и малые дыхательные пути: существует ли взаимосвязь?
Об авторах
А. И. Синопальников
Российская медицинская академия последипломного образования
Россия
Россия
д.м.н., профессор, зав. кафедрой пульмонологии
123995, Москва, ул. Баррикадная, 2 / 1. Тел.: 8-495-263-53-72; 8-916-634 65 52.
Ю. Г. Белоцерковская
Российская медицинская академия последипломного образования
Россия
Россия
к. м. н.; доцент кафедры пульмонологии
123995, Москва, ул. Баррикадная, 2 / 1. Тел.: 8-495-263-53-72, 8-916-645 50 27.
Список литературы
1. GINA Report. Global Strategy for Asthma Management and Prevention. Updated 2010. The GINA reports are available on www.ginasthma.org
2. Demoly P., Paggiaro P., Plaza V. et al. Prevalence of asthma control among adults in France, Germany, Italy, Spain and the UK. Eur. Respir. Rev. 2009; 18 (112): 105e12.
3. Demoly P., Gueron B., Annunziata K. et al. Update on asthma control in five European countries: results of a 2008 survey. Eur. Respir. Rev. 2010; 19 (116): 150e7.
4. Hodder R. The paradox of adult asthma control: "Who's in control anyway?" Can. Respir. J. 2007; 14 (4): 229–234.
5. Suzuki T., Saito I., Adachi M. et al. Influence of patients' adherence to medication, patient background and physicians' compliance to the guidelines on asthma control. Yakugaku Zasshi 2011; 131 (1): 129–138.
6. Spallarossa D., Battistini E., Silvestri M. et al. Steroid-naïve adolescents with mild intermittent allergic asthma have airway hyperresponsiveness and elevated exhaled nitric oxide levels. J. Asthma 2003; 40: 301–310.
7. Bjermer L. Time for a paradigm shift in asthma treatment: from relieving bronchospasm to controlling systemic inflammation. J. Allergy Clin. Immunol. 2007; 120: 1269–1275.
8. Macklem P.T. The physiology of small airways. Am. J. Respir. Crit. Care Med. 1998; 157: 181–183.
9. Scichilone N., Battaglia S., Olivieri D., Bellia V. The role of small airways in monitoring the response to asthma treatment: what is beyond FEV1? Allergy 2009; 64:1563–1569.
10. Frey U., Suki B. Complexity of chronic asthma and chronic obstructive pulmonary disease: implications for risk assessment, and disease progression and control. Lancet 2008; 372: 1088–1099.
11. Beigelman4Aubry C., Capderou A., Grenier P.A. et al. Mild intermittent asthma: CT assessment of bronchial cross-sectional area and lung attenuation at controlled lung volume. Radiology 2002; 223: 181–187.
12. Ueda T., Niimi A., Matsumoto H. et al. Role of small airways in asthma: investigation using high-resolution computed tomography. J. Allergy Clin. Immunol. 2006; 118: 1019–1025.
13. Bourdin A., Paganin F., Prefaut C. et al. Nitrogen washout slope in poorly controlled asthma. Allergy 2006; 61: 85–89.
14. Battaglia S., den Hertog H., Timmers M.C. et al. Small airways function and molecular markers in exhaled air in mild asthma. Thorax 2005; 60: 639–644.
15. Lehtimaki L., Kankaanranta H., Saarelainen S. et al. Increased alveolar nitric oxide concentration in asthmatic patients with nocturnal symptoms. Eur. Respir. J. 2002; 20: 841–845.
16. Berry M., Hargadon B., Morgan A. et al. Alveolar nitric oxide in adults with asthma: evidence of distal lung inflammation in refractory asthma. Eur. Respir. J. 2005; 25: 986–991.
17. Yixin S., Aledia A.S., Tatavoosian A.V. et al. Relating small airways to asthma control by using impulse oscillometry in children. J. Allergy Clin. Immunol. 2012; 129: 671–678.
18. Yanai M., Sekizawa K., Ohrui T. et al. Site of airway obstruction in pulmonary disease: direct measurement of intrabronchial pressure. J. Appl. Physiol. 1992; 72: 1016–1023.
19. Dolhnikoff M., da Silva L.F., de Araujo B.B. et al. The outer wall of small airways is a major site of remodeling in fatal asthma. J. Allergy Clin. Immunol. 2009; 123: 1090–1097.
20. Balzar S., Chu H.W., Strand M., Wenzel S. Relationship of small airway chymase-positive mast cells and lung function in severe asthma. Am. J. Respir. Crit. Care Med. 2005; 171: 431–439.
21. Wenzel S.E., Szefler S.J., Leung D.Y. et al. Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids. Am. J. Respir. Crit. Care Med. 1997; 156: 737–743.
22. Kraft M., Martin R.J., Wilson S. et al. Lymphocyte and eosinophil influx into alveolar tissue in nocturnal asthma. Am. J. Respir. Crit. Care Med. 1999; 159: 228–234.
23. The ENFUMOSA Study Group. The ENFUMOSA crosssectional European multicentre study of the clinical phenotype of chronic severe asthma. Eur. Respir. J. 2003; 22: 470–477.
24. Lange P., Parner J., Vestbo J. et al. A 15-year follow-up study of ventilatory function in adults with asthma. N. Engl. J. Med. 1998; 339: 1194–1200.
25. Kizkin O., Turker G., Hacievliyagil S.S., Gunen H. Asthma, age, and early reversibility testing. J. Asthma 2003; 40: 317–321.
26. Cassino C., Berger K.I., Goldring R.M. et al. Duration of asthma and physiologic outcomes in elderly nonsmokers. Am. J. Respir. Crit. Care Med. 2000; 162: 1423–1428.
27. Thomson N.C., Chaudhuri R. Asthma in smokers: challenges and opportunities. Curr. Opin. Pulm. Med. 2009; 15: 39–45.
28. Broekema M., ten Hacken N.H., Volbeda F. et al. Airway epithelial changes in smokers but not in ex-smokers with asthma. Am. J. Respir. Crit. Care Med. 2009; 180: 1170–1178.
29. Stanescu D., Sanna A., Veriter C., Robert A. Identification of smokers susceptible to development of chronic airflow limitation: a 13-year followup. Chest 1998; 114: 416–425.
30. Contoli M., Kraft M., Hamid Q. et al. Do small airway abnormalities characterize asthma phenotypes? In search of proof. Clin. Exp. Allergy 2012; 42: 1150–1160.
31. Bateman E.D., Boushey H.A., Bousquet J. et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am. J. Respir. Crit. Care Med. 2004; 170 (8): 836–844.
32. Greening A.P., Ind P.W., Northfield M. et al. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994; 344: 219–224.
33. Pauwels R.A., Lofdahl C.G., Postma D.S. et al; Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N. Engl. J. Med. 1997; 337: 1405–1411.
34. Barnes P.J., Nicolini G., Bizzi A. et al. Do inhaled corticosteroid / long-acting beta2-agonist fixed combinations provide superior clinical benefits compared with separate inhalers? A literature reappraisal. Allergy and Asthma 2012; 33: 140–144.
35. Huchon G., Magnussen H., Chuchalin A. et al. Lung function and asthma control with beclomethasone and formoterol in a single inhaler. Respir. Med. 2009; 103: 41–49.
36. Bateman E.D., Btitton M., Carrillo J. et al. Salmeterol / fluticasone combination inhaler: A new, effective and well tolerated treatment for asthma. Clin. Drug Invest. 1998; 16: 193–201.
37. Chapman K.R., Ringdal N., Backer V. et al. Salmeterol and fluticasone propionate (50/250 microg) administered via combination Discus inhaler: As effective as when given via separate Diskus inhalers. Can. Respir. J. 1999; 6: 45–51.
38. Aubier M., Pieters W.R., Schlosser N.J., Steinmetz K.O. Salmeterol / fluticasone propionate (50 / 500 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma. Respir. Med. 1999; 93: 876–884.
39. Zetterstrom O., Buhl R., Mellem H. et al. Improved asthma control with budesonide / formoterol in a single inhaler, compared with budesonide alone. Eur. Respir. J. 2001; 18: 262–268.
40. Rosenhall L., Heinig J.H., Lindqvist A. et al. Budesonide / formoterol (Symbicort) is well tolerated and effective in patients with moderate persistent asthma. Int. J. Clin. Pract. 2002; 56: 427–433.
41. Rosenhall L., Elvstrand A., Tilling B. et al. One-year safety and efficacy of budesonide / formoterol in a single inhaler (Symbicort Turbuhaler) for the treatment of asthma. Respir. Med. 2003; 97: 702–708.
42. Jenkins C., Kolarikova R., Kuna P. et al. Efficacy and safety of high-dose budesonide / formoterol (Symbicort) compared with budesonide administered either concomitantly with formoterol or alone in patients with persistent symptomatic asthma. Respirology 2006; 11: 276–286.
43. Chervinsky P., Baker J., Bensch G. et al. Patient-reported outcomes in adults with moderate to severe asthma after use of budesonide and formoterol administered via 1 pressurized metered-dose inhaler. Ann. Allergy Asthma Immunol. 2008; 101: 463–473.
44. Bodzenta4Lukaszyk A., Pulka G., Dymek A. et al. Efficacy and safety of fluticasone and formoterol in a single pressurized metered dose inhaler. Respir. Med. 2011; 105: 674–682.
45. Papi A., Paggiaro P.L., Nicolini G. et al. Beclomethasone / formoterol versus budesonide / formoterol combination therapy in asthma. Eur. Respir. J. 2007; 29 (4): 682–689.
46. Papi A., Paggiaro P., Nicolini G. et al. Beclomethasone / formoterol vs fluticasone / salmeterol inhaled combination in moderate to severe asthma. Allergy 2007; 62 (10): 1182–1188.
47. Muller V., Galffy G., Eszes N. et al. Asthma control in patients receiving inhaled corticosteroid and long-acting beta2-agonist fixed combinations. A real-life study comparing dry powder inhalers and a pressurized metered dose inhaler extrafine formulation. BMC Pulm. Med. 2011; 11: 40–48.
48. Allegra L., Cremonesi G., Girbinoet G. et al. Real-life prospective study on asthma control in Italy: Cross-sectional phase results. Respir. Med. 2011; doi:10.1016/j.rmed. 2011.10.001
Рецензия
Для цитирования:
Синопальников А.И., Белоцерковская Ю.Г. Контроль над бронхиальной астмой и малые дыхательные пути: существует ли взаимосвязь? Пульмонология. 2012;(6):127-134. https://doi.org/10.18093/0869-0189-2012-0-6-127-134
For citation:
Sinopalnikov A.I., Belotserkovskaya Yu.G. Asthma control and small airways: is there relationship? PULMONOLOGIYA. 2012;(6):127-134. (In Russ.) https://doi.org/10.18093/0869-0189-2012-0-6-127-134
Просмотров:
732
Послать статью по эл. почте 